Calamos Advisors LLC Takes $992,000 Position in Revolution Medicines, Inc. $RVMD

Key Points

• Calamos Advisors LLC initiated a new position in Revolution Medicines (NASDAQ:RVMD) in Q4, buying 12,460 shares worth about $992,000.
• Insiders have been net sellers recently — 184,592 shares sold (~$24.5M) in the past 90 days — while institutional investors hold 94.34% of the stock and insiders own 8.20%.
• RVMD shares opened at $131.67, with a 12‑month range of $34.00–$155.70; the company missed quarterly EPS estimates (reported -$1.86 vs. est. -$1.56) but carries a MarketBeat consensus "Buy" rating and a $78.94 price target.

Calamos Advisors LLC purchased a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 12,460 shares of the company's stock, valued at approximately $992,000.

A number of other large investors have also added to or reduced their stakes in RVMD. Nextech Invest Ltd. increased its stake in Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock worth $332,472,000 after acquiring an additional 1,304,347 shares during the period. Millennium Management LLC lifted its position in shares of Revolution Medicines by 681.8% during the 1st quarter. Millennium Management LLC now owns 156,353 shares of the company's stock valued at $5,529,000 after acquiring an additional 136,353 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Revolution Medicines by 14.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company's stock worth $10,615,000 after purchasing an additional 37,345 shares in the last quarter. Invesco Ltd. increased its position in shares of Revolution Medicines by 19.3% in the second quarter. Invesco Ltd. now owns 227,019 shares of the company's stock worth $8,352,000 after purchasing an additional 36,760 shares during the period. Finally, Jump Financial LLC increased its position in shares of Revolution Medicines by 87.9% in the second quarter. Jump Financial LLC now owns 15,258 shares of the company's stock worth $561,000 after purchasing an additional 7,137 shares during the period. Institutional investors and hedge funds own 94.34% of the company's stock.

Revolution Medicines Price Performance

Shares of RVMD stock opened at $131.67 on Tuesday. The business has a fifty day simple moving average of $108.27 and a 200 day simple moving average of $90.40. The company has a market cap of $26.09 billion, a P/E ratio of -22.28 and a beta of 1.01. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.16. Revolution Medicines, Inc. has a twelve month low of $34.00 and a twelve month high of $155.70.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.30). During the same quarter in the previous year, the company posted ($1.12) earnings per share. On average, sell-side analysts forecast that Revolution Medicines, Inc. will post -7.42 EPS for the current fiscal year.

Insider Activity at Revolution Medicines

In related news, COO Margaret A. Horn sold 4,583 shares of the company's stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $455,916.84. Following the completion of the transaction, the chief operating officer directly owned 157,570 shares in the company, valued at $15,675,063.60. This represents a 2.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Xiaolin Wang sold 2,010 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $199,954.80. Following the completion of the transaction, the insider directly owned 116,063 shares of the company's stock, valued at approximately $11,545,947.24. The trade was a 1.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 184,592 shares of company stock worth $24,499,532 in the last ninety days. Insiders own 8.20% of the company's stock.

Analyst Ratings Changes

Several research firms recently weighed in on RVMD. UBS Group initiated coverage on shares of Revolution Medicines in a research report on Friday, February 27th. They set a "buy" rating for the company. Stifel Nicolaus reissued a "buy" rating on shares of Revolution Medicines in a report on Monday, April 20th. Benchmark restated an "overweight" rating on shares of Revolution Medicines in a research report on Tuesday, February 17th. Jefferies Financial Group assumed coverage on shares of Revolution Medicines in a report on Monday, March 16th. They set a "buy" rating for the company. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Revolution Medicines in a research report on Tuesday, April 21st. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $78.94.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.